News
![u-blox AG: u-blox to host Capital Markets Day](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
u-blox AG: u-blox to host Capital Markets Day
![u-blox AG: u-blox announces results of Extraordinary Shareholder’s Meeting](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
u-blox AG: u-blox announces results of Extraordinary Shareholder’s Meeting
![Energy transition and sustainability at the forefront of our thinking](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Energy transition and sustainability at the forefront of our thinking
![Kardex adjusts margin target for 2022](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Kardex adjusts margin target for 2022
![EQS-News: Significantly positive sales development at the Highlight Group](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
EQS-News: Significantly positive sales development at the Highlight Group
![Key Figures
15.11.2022](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Key Figures 15.11.2022
![GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab: https://mms.businesswire.com/media/20210924005283/en/519367/5/GeNeuro_-_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmd6Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--53c763e003e9941ae7f8661390efa77b05957b7c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/GeNeuro_-_logo.jpg?locale=us)
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
GeNeuro (Paris:GNRO)(Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such
![GeNeuro meldet erste Patientenrekrutierungen in allen fünf schweizerischen Zentren für die erste klinische Studie mit Temelimab zur personalisierten Medizin gegen Long COVID: https://mms.businesswire.com/media/20210924005283/en/519367/5/GeNeuro_-_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmd6Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--53c763e003e9941ae7f8661390efa77b05957b7c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/GeNeuro_-_logo.jpg?locale=us)
GeNeuro meldet erste Patientenrekrutierungen in allen fünf schweizerischen Zentren für die erste klinische Studie mit Temelimab zur personalisierten Medizin gegen Long COVID
GeNeuro (Euronext Paris: CH0308403085 - GNRO), ein biopharmazeutisches Unternehmen, das sich darauf konzentriert, die kausalen Faktoren zu stoppen, die das Fortschreiten von neurodegenerativen und
![GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab: https://mms.businesswire.com/media/20210924005283/en/519367/5/GeNeuro_-_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmd6Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--53c763e003e9941ae7f8661390efa77b05957b7c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/GeNeuro_-_logo.jpg?locale=us)
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple
![Orascom Development Holding AG: has released its consolidated financial results for 9M 2022](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Orascom Development Holding AG: has released its consolidated financial results for 9M 2022
![Comet confirms growth targets at Capital Markets Day, short-term softening expected](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Comet confirms growth targets at Capital Markets Day, short-term softening expected
![EQS-News: Highlight Communications AG: Personnel](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
EQS-News: Highlight Communications AG: Personnel
![Cicor strengthens presence in Germany through the acquisition of Phoenix Mecano Digital Elektronik and Phoenix Mecano Digital Tunisie](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Cicor strengthens presence in Germany through the acquisition of Phoenix Mecano Digital Elektronik and Phoenix Mecano Digital Tunisie
![Phoenix Mecano streamlines its Industrial Components business](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Phoenix Mecano streamlines its Industrial Components business
![Orascom Development Holding AG: announces its Egyptian Subsidiary (ODE) 9M 2022 Financial Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Orascom Development Holding AG: announces its Egyptian Subsidiary (ODE) 9M 2022 Financial Results
![Implenia extends syndicated loan agreement and secures long-term financing](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Implenia extends syndicated loan agreement and secures long-term financing
![ZÜBLIN IMMOBILIEN HOLDING AG / Publication of Semi-Annual Report 2022/23 as of 30 September 2022](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
ZÜBLIN IMMOBILIEN HOLDING AG / Publication of Semi-Annual Report 2022/23 as of 30 September 2022
![Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil
![Swiss Steel Group saw expected slowdown in activity in Q3 2022](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Swiss Steel Group saw expected slowdown in activity in Q3 2022
![Meyer Burger successfully completes its capital increase of CHF 250 million](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Meyer Burger successfully completes its capital increase of CHF 250 million
![Meyer Burger announces 97.23 percent of the maximum number of offered shares were subscribed via the exercise of rights](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Meyer Burger announces 97.23 percent of the maximum number of offered shares were subscribed via the exercise of rights
![LEM announces results for H1 2022/23: record sales and EBIT](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
LEM announces results for H1 2022/23: record sales and EBIT
![CREALOGIX’ new research suggests investors want support to adopt crypto](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
CREALOGIX’ new research suggests investors want support to adopt crypto
![Private Equity Holding AG: Half Year-Report as of September 30, 2022](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Private Equity Holding AG: Half Year-Report as of September 30, 2022
![Phoenix Mecano posts further increase in profitability](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)